vs
Side-by-side financial comparison of Quest Diagnostics (DGX) and Zoetis (ZTS). Click either name above to swap in a different company.
Quest Diagnostics is the larger business by last-quarter revenue ($2.9B vs $2.4B, roughly 1.2× Zoetis). Zoetis runs the higher net margin — 25.3% vs 9.7%, a 15.6% gap on every dollar of revenue. On growth, Quest Diagnostics posted the faster year-over-year revenue change (9.2% vs 3.0%). Over the past eight quarters, Quest Diagnostics's revenue compounded faster (9.9% CAGR vs 4.4%).
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
DGX vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $2.4B |
| Net Profit | $281.0M | $603.0M |
| Gross Margin | — | 70.2% |
| Operating Margin | 15.4% | 31.9% |
| Net Margin | 9.7% | 25.3% |
| Revenue YoY | 9.2% | 3.0% |
| Net Profit YoY | 12.0% | 3.8% |
| EPS (diluted) | $2.24 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.9B | — | ||
| Q4 25 | $2.8B | $2.4B | ||
| Q3 25 | $2.8B | $2.4B | ||
| Q2 25 | $2.8B | $2.5B | ||
| Q1 25 | $2.7B | $2.2B | ||
| Q4 24 | $2.6B | $2.3B | ||
| Q3 24 | $2.5B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B |
| Q1 26 | $281.0M | — | ||
| Q4 25 | $245.0M | $603.0M | ||
| Q3 25 | $245.0M | $721.0M | ||
| Q2 25 | $282.0M | $718.0M | ||
| Q1 25 | $220.0M | $631.0M | ||
| Q4 24 | $222.0M | $581.0M | ||
| Q3 24 | $226.0M | $682.0M | ||
| Q2 24 | $229.0M | $624.0M |
| Q1 26 | — | — | ||
| Q4 25 | 32.4% | 70.2% | ||
| Q3 25 | 33.7% | 71.5% | ||
| Q2 25 | 34.2% | 73.6% | ||
| Q1 25 | 32.5% | 72.0% | ||
| Q4 24 | 32.7% | 69.5% | ||
| Q3 24 | 32.6% | 70.6% | ||
| Q2 24 | 33.5% | 71.7% |
| Q1 26 | 15.4% | — | ||
| Q4 25 | 13.8% | 31.9% | ||
| Q3 25 | 13.7% | 37.0% | ||
| Q2 25 | 15.9% | 36.7% | ||
| Q1 25 | 13.0% | 36.5% | ||
| Q4 24 | 13.8% | 31.6% | ||
| Q3 24 | 13.3% | 36.6% | ||
| Q2 24 | 14.8% | 33.0% |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 8.7% | 25.3% | ||
| Q3 25 | 8.7% | 30.0% | ||
| Q2 25 | 10.2% | 29.2% | ||
| Q1 25 | 8.3% | 28.4% | ||
| Q4 24 | 8.5% | 25.1% | ||
| Q3 24 | 9.1% | 28.6% | ||
| Q2 24 | 9.6% | 26.4% |
| Q1 26 | $2.24 | — | ||
| Q4 25 | $2.18 | $1.37 | ||
| Q3 25 | $2.16 | $1.63 | ||
| Q2 25 | $2.47 | $1.61 | ||
| Q1 25 | $1.94 | $1.41 | ||
| Q4 24 | $1.95 | $1.29 | ||
| Q3 24 | $1.99 | $1.50 | ||
| Q2 24 | $2.03 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $393.0M | — |
| Total DebtLower is stronger | $5.7B | — |
| Stockholders' EquityBook value | $7.7B | $3.3B |
| Total Assets | $16.7B | $15.5B |
| Debt / EquityLower = less leverage | 0.74× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $393.0M | — | ||
| Q4 25 | $420.0M | — | ||
| Q3 25 | $432.0M | $2.1B | ||
| Q2 25 | $319.0M | $1.4B | ||
| Q1 25 | $188.0M | $1.7B | ||
| Q4 24 | $549.0M | $2.0B | ||
| Q3 24 | $764.0M | $1.7B | ||
| Q2 24 | $271.0M | $1.6B |
| Q1 26 | $5.7B | — | ||
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | — | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $5.9B | — | ||
| Q4 24 | $5.6B | — | ||
| Q3 24 | $5.6B | — | ||
| Q2 24 | $3.8B | — |
| Q1 26 | $7.7B | — | ||
| Q4 25 | $7.2B | $3.3B | ||
| Q3 25 | $7.3B | $5.4B | ||
| Q2 25 | $7.2B | $5.0B | ||
| Q1 25 | $6.9B | $4.7B | ||
| Q4 24 | $6.8B | $4.8B | ||
| Q3 24 | $6.8B | $5.2B | ||
| Q2 24 | $6.6B | $5.0B |
| Q1 26 | $16.7B | — | ||
| Q4 25 | $16.2B | $15.5B | ||
| Q3 25 | $16.2B | $15.2B | ||
| Q2 25 | $16.0B | $14.5B | ||
| Q1 25 | $15.8B | $14.1B | ||
| Q4 24 | $16.2B | $14.2B | ||
| Q3 24 | $16.1B | $14.4B | ||
| Q2 24 | $13.9B | $14.2B |
| Q1 26 | 0.74× | — | ||
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.72× | — | ||
| Q1 25 | 0.85× | — | ||
| Q4 24 | 0.83× | — | ||
| Q3 24 | 0.83× | — | ||
| Q2 24 | 0.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $278.0M | $893.0M |
| Free Cash FlowOCF − Capex | — | $732.0M |
| FCF MarginFCF / Revenue | — | 30.7% |
| Capex IntensityCapex / Revenue | 3.9% | 6.7% |
| Cash ConversionOCF / Net Profit | 0.99× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $278.0M | — | ||
| Q4 25 | $465.0M | $893.0M | ||
| Q3 25 | $563.0M | $938.0M | ||
| Q2 25 | $544.0M | $486.0M | ||
| Q1 25 | $314.0M | $587.0M | ||
| Q4 24 | $464.0M | $905.0M | ||
| Q3 24 | $356.0M | $951.0M | ||
| Q2 24 | $360.0M | $502.0M |
| Q1 26 | — | — | ||
| Q4 25 | $307.0M | $732.0M | ||
| Q3 25 | $419.0M | $805.0M | ||
| Q2 25 | $436.0M | $308.0M | ||
| Q1 25 | $197.0M | $438.0M | ||
| Q4 24 | $341.0M | $689.0M | ||
| Q3 24 | $250.0M | $784.0M | ||
| Q2 24 | $268.0M | $370.0M |
| Q1 26 | — | — | ||
| Q4 25 | 10.9% | 30.7% | ||
| Q3 25 | 14.9% | 33.5% | ||
| Q2 25 | 15.8% | 12.5% | ||
| Q1 25 | 7.4% | 19.7% | ||
| Q4 24 | 13.0% | 29.7% | ||
| Q3 24 | 10.0% | 32.8% | ||
| Q2 24 | 11.2% | 15.7% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 5.6% | 6.7% | ||
| Q3 25 | 5.1% | 5.5% | ||
| Q2 25 | 3.9% | 7.2% | ||
| Q1 25 | 4.4% | 6.7% | ||
| Q4 24 | 4.7% | 9.3% | ||
| Q3 24 | 4.3% | 7.0% | ||
| Q2 24 | 3.8% | 5.6% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.90× | 1.48× | ||
| Q3 25 | 2.30× | 1.30× | ||
| Q2 25 | 1.93× | 0.68× | ||
| Q1 25 | 1.43× | 0.93× | ||
| Q4 24 | 2.09× | 1.56× | ||
| Q3 24 | 1.58× | 1.39× | ||
| Q2 24 | 1.57× | 0.80× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DGX
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
